Neural substrates of cue reactivity: Association with treatment outcomes and relapse

Addiction Biology

Volumn 21, Issue 1, 2016, Pages 3-22

  Courtney, Kelly E ^a   Schacht, Joseph P ^b   Hutchison, Kent ^c   Roche, Daniel J O ^a   Ray, Lara A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Addiction; cue reactivity; fMRI; medication development; substance use disorder; treatment

Indexed keywords

ACAMPROSATE; ALCOHOL; AMFEBUTAMONE; AMISULPRIDE; ARIPIPRAZOLE; BACLOFEN; COCAINE; CYCLOSERINE; ESCITALOPRAM; FLUMAZENIL; GABAPENTIN; GUANFACINE; MODAFINIL; NALTREXONE; NICOTINE; ONDANSETRON; OPIATE; VARENICLINE;

ALCOHOLISM; BEHAVIOR; COCAINE DEPENDENCE; COGNITIVE THERAPY; DRUG DEPENDENCE; DRUG EFFECT; EXERCISE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MOTIVATION; NEUROBIOLOGY; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROSCIENCE; NONHUMAN; OPIATE ADDICTION; PREDICTION; PRIORITY JOURNAL; RELAPSE; REVIEW; REWARD; SMOKING; SMOKING CESSATION; SOCIAL PSYCHOLOGY; SUBSTANCE ABUSE; TREATMENT OUTCOME; TREATMENT RESPONSE; ASSOCIATION; BRAIN; COCAINE-RELATED DISORDERS; FUNCTIONAL NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPIOID-RELATED DISORDERS; PATHOPHYSIOLOGY; PROGNOSIS; RECURRENT DISEASE; TOBACCO USE DISORDER; TRANSLATIONAL RESEARCH;

ALCOHOLISM; BRAIN; COCAINE-RELATED DISORDERS; CUES; FUNCTIONAL NEUROIMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; OPIOID-RELATED DISORDERS; PROGNOSIS; RECURRENCE; TOBACCO USE DISORDER; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84957431998     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/adb.12314     Document Type: Review

References (111)

1. Bach P, Vollsta Dt-Klein S, Kirsch M, Hoffmann S, Jorde A, Frank J, Charlet K, Beck A, Heinz A, Walter H, Sommer WH, Spanagel R, Rietschel M, Kiefer F, (2015) Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: a functional imaging study in alcohol dependent subjects. Eur Neuropsychopharmacol 8: 1128-1135.
2. Baxter MG, Murray EA, (2002) The amygdala and reward. Nat Rev Neurosci 3: 563-573.
3. Bechara A, (2005) Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective. Nat Neurosci 8: 1458-1463.
4. Beck A, Wustenberg T, Genauck A, Wrase J, Schlagenhauf F, Smolka MN, Mann K, Heinz A, (2012) Effect of brain structure, brain function, and brain connectivity on relapse in alcohol-dependent patients. Arch Gen Psychiatry 69: 842-852.
5. Berridge K, Kringelbach M, (2008) Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology (Berl) 199: 457-480.
6. Berridge KC, Robinson TE, (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28: 309-369.
7. Brody AL, Mandelkern MA, Olmstead RE, Jou J, Tiongson E, Allen V, Scheibal D, London ED, Monterosso JR, Tiffany ST, Korb A, Gan JJ, Cohen MS, (2007a) Neural substrates of resisting craving during cigarette cue exposure. Biol Psychiatry 62: 642-651.
8. Brody AL, Mandelkern MA, Olmstead RE, Jou J, Tiongson E, Allen V, Scheibal D, London ED, Monterosso JR, Tiffany ST, Korb A, Gan JJ, Cohen MS, (2007b) Neural substrates of resisting craving during cigarette cue exposure. Biol Psychiatry 62: 642-651.
9. Bush G, Luu P, Posner MI, (2000) Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci 4: 215-222.
10. Camara E, Rodriguez-Fornells A, Ye Z, Munte TF, (2009) Reward networks in the brain as captured by connectivity measures. Front Neurosci 3: 350-362.
11. Cardenas VA, Durazzo TC, Gazdzinski S, Mon A, Studholme C, Meyerhoff DJ, (2011) Brain morphology at entry into treatment for alcohol dependence is related to relapse propensity. Biol Psychiatry 70: 561-567.
12. Chase HW, Eickhoff SB, Laird AR, Hogarth L, (2011) The neural basis of drug stimulus processing and craving: an activation likelihood estimation meta-analysis. Biol Psychiatry 70: 785-793.
13. Chua HF, Ho SS, Jasinska AJ, Polk TA, Welsh RC, Liberzon I, Strecher VJ, (2011) Self-related neural response to tailored smoking-cessation messages predicts quitting. Nat Neurosci 14: 426-427.
14. Conklin CA, Tiffany ST, (2002) Applying extinction research and theory to cue-exposure addiction treatments. Addiction 97: 155-167.
15. Courtney KE, Ghahremani DG, Ray LA, (2013) The effects of varenicline and naltrexone, alone and in combination, on neural responses to alcohol cues in heavy drinking smokers. Alcohol Clin Exp Res 37: S2.
16. Culbertson CS, Bramen J, Cohen MS, London ED, Olmstead RE, Gan JJ, Costello MR, Shulenberger S, Mandelkern MA, Brody AL, (2011) Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers. Arch Gen Psychiatry 68: 505-515.
17. Drummond DC, (2000) What does cue-reactivity have to offer clinical research? Addiction 95 Suppl 2: S129-144.
18. Drummond DC, Litten RZ, Lowman C, Hunt WA, (2000) Craving research: future directions. Addiction 95: S247-S255.
19. Durazzo TC, Tosun D, Buckley S, Gazdzinski S, Mon A, Fryer SL, Meyerhoff DJ, (2011) Cortical thickness, surface area, and volume of the brain reward system in alcohol dependence: relationships to relapse and extended abstinence. Alcohol Clin Exp Res 35: 1187-1200.
20. Engelmann JM, Versace F, Robinson JD, Minnix JA, Lam CY, Cui Y, Brown VL, Cinciripini PM, (2012) Neural substrates of smoking cue reactivity: a meta-analysis of fMRI studies. Neuroimage 60: 252-262.
21. Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, Robbins TW, (1999) Associative processes in addiction and reward the role of amygdala-ventral striatal subsystems. Ann N Y Acad Sci 877: 412-438.
22. Everitt BJ, Robbins TW, (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8: 1481-1489.
23. Feduccia AA, Simms JA, Mill D, Yi HY, Bartlett SE, (2014) Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens. Br J Pharmacol 171: 3420-3431.
24. Feldstein Ewing SW, Filbey FM, Sabbineni A, Chandler LD, Hutchison KE, (2011) How psychosocial alcohol interventions work: a preliminary look at what FMRI can tell us. Alcohol Clin Exp Res 35: 643-651.
25. Filbey FM, Claus E, Audette AR, Niculescu M, Banich MT, Tanabe J, Du YP, Hutchison KE, (2008) Exposure to the taste of alcohol elicits activation of the mesocorticolimbic neurocircuitry. Neuropsychopharmacology 33: 1391-1401.
26. Flagel SB, Clark JJ, Robinson TE, Mayo L, Czuj A, Willuhn I, Akers CA, Clinton SM, Phillips PE, Akil H, (2011) A selective role for dopamine in stimulus-reward learning. Nature 469: 53-57.
27. Flagel SB, Robinson TE, Clark JJ, Clinton SM, Watson SJ, Seeman P, Phillips PE, Akil H, (2010) An animal model of genetic vulnerability to behavioral disinhibition and responsiveness to reward-related cues: implications for addiction. Neuropsychopharmacology 35: 388-400.
28. Fox HC, Seo D, Tuit K, Hansen J, Kimmerling A, Morgan PT, Sinha R, (2012) Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: preliminary findings. J Psychopharmacol 26: 958-972.
29. Franklin T, Wang Z, Suh JJ, Hazan R, Cruz J, Li Y, Goldman M, Detre JA, O'Brien CP, Childress AR, (2011) Effects of varenicline on smoking cue-triggered neural and craving responses. Arch Gen Psychiatry 68: 516-526.
30. Fu CH, Costafreda SG, (2013) Neuroimaging-based biomarkers in psychiatry: clinical opportunities of a paradigm shift. Can J Psychiatry 58: 499-508.
31. Garrison GD, Dugan SE, (2009) Varenicline: a first-line treatment option for smoking cessation. Clin Ther 31: 463-491.
32. Goldstein RZ, Volkow ND, (2011) Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci 12: 652-669.
33. Goudriaan AE, Veltman DJ, van den Brink W, Dom G, Schmaal L, (2013) Neurophysiological effects of modafinil on cue-exposure in cocaine dependence: a randomized placebo-controlled cross-over study using pharmacological fMRI. Addict Behav 38: 1509-1517.
34. Grüsser SM, Wrase J, Klein S, Hermann D, Smolka MN, Ruf M, Weber-Fahr W, Flor H, Mann K, Braus DF, Heinz A, (2004) Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. Psychopharmacology (Berl) 175: 296-302.
35. Han DH, Kim SM, Choi JE, Min KJ, Renshaw PF, (2013) Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence. J Psychopharmacol 27: 282-291.
36. Hare TA, Camerer CF, Rangel A, (2009) Self-control in decision-making involves modulation of the vmPFC valuation system. Science 324: 646-648.
37. Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF, (2013) DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry 170: 834-851.
38. Hermann D, Smolka MN, Wrase J, Klein S, Nikitopoulos J, Georgi A, Braus DF, Flor H, Mann K, Heinz A, (2006) Blockade of cue-induced brain activation of abstinent alcoholics by a single administration of amisulpride as measured with fMRI. Alcohol Clin Exp Res 30: 1349-1354.
39. Janes AC, Frederick B, Richardt S, Burbridge C, Merlo-Pich E, Renshaw PF, Evins AE, Fava M, Kaufman MJ, (2009) Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence. Exp Clin Psychopharmacol 17: 365-373.
40. Janes AC, Pizzagalli DA, Richardt S, deB Frederick B, Chuzi S, Pachas G, Culhane MA, Holmes AJ, Fava M, Evins AE, Kaufman MJ, (2010) Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol Psychiatry 67: 722-729.
41. Janse Van Rensburg K, Taylor A, Benattayallah A, Hodgson T, (2012) The effects of exercise on cigarette cravings and brain activation in response to smoking-related images. Psychopharmacology (Berl) 221: 659-666.
42. Jasinska AJ, Stein EA, Kaiser J, Naumer MJ, Yalachkov Y, (2014) Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies. Neurosci Biobehav Rev 38: 1-16.
43. Jorde A, Bach P, Witt SH, Becker K, Reinhard I, Vollstadt-Klein S, Kirsch M, Hermann D, Charlet K, Beck A, Wimmer L, Frank J, Treutlein J, Spanagel R, Mann K, Walter H, Heinz A, Rietschel M, Kiefer F, (2014) Genetic variation in the atrial natriuretic peptide transcription factor GATA4 modulates amygdala responsiveness in alcohol dependence. Biol Psychiatry 75: 790-797.
44. Kahn R, Biswas K, Childress AR, Shoptaw S, Fudala PJ, Gorgon L, Montoya I, Collins J, McSherry F, Li SH, Chiang N, Alathari H, Watson D, Liberto J, Beresford T, Stock C, Wallace C, Gruber V, Elkashef A, (2009) Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug Alcohol Depend 103: 59-64.
45. Kalivas PW, (2009) The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 10: 561-572.
46. Kalivas PW, Volkow ND, (2005) The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162: 1403-1413.
47. Kauer JA, Malenka RC, (2007) Synaptic plasticity and addiction. Nat Rev Neurosci 8: 844-858.
48. Kiefer F, Kirsch M, Bach P, Hoffmann S, Reinhard I, Jorde A, von der Goltz C, Spanagel R, Mann K, Loeber S, Vollstadt-Klein S, (2015) Effects of d -cycloserine on extinction of mesolimbic cue reactivity in alcoholism: a randomized placebo-controlled trial. Psychopharmacology (Berl) 232: 2353-2362.
49. Konova AB, Moeller SJ, Goldstein RZ, (2013) Common and distinct neural targets of treatment: changing brain function in substance addiction. Neurosci Biobehav Rev 37: 2806-2817.
50. Koob GF, Le Moal M, (2005) Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci 8: 1442-1444.
51. Koob GF, Volkow ND, (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35: 217-238.
52. Kosten TR, Scanley BE, Tucker KA, Oliveto A, Prince C, Sinha R, Potenza MN, Skudlarski P, Wexler BE, (2006) Cue-induced brain activity changes and relapse in cocaine-dependent patients. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 31: 644-650.
53. Langleben DD, Ruparel K, Elman I, Busch-Winokur S, Pratiwadi R, Loughead J, O'Brien CP, Childress AR, (2008) Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. Am J Psychiatry 165: 390-394.
54. Langosch JM, Spiegelhalder K, Jahnke K, Feige B, Regen W, Kiemen A, Hennig J, Olbrich HM, (2012) The impact of acamprosate on cue reactivity in alcohol dependent individuals: a functional magnetic resonance imaging study. J Clin Psychopharmacol 32: 661-665.
55. Le Merrer J, Becker JA, Befort K, Kieffer BL, (2009) Reward processing by the opioid system in the brain. Physiol Rev 89: 1379-1412.
56. Leggio L, Kenna GA, Swift RM, (2008) New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Prog Neuropsychopharmacol Biol Psychiatry 32: 1106-1117.
57. Li X, Hartwell KJ, Borckardt J, Prisciandaro JJ, Saladin ME, Morgan PS, Johnson KA, Lematty T, Brady KT, George MS, (2013) Volitional reduction of anterior cingulate cortex activity produces decreased cue craving in smoking cessation: a preliminary real-time fMRI study. Addict Biol 18: 739-748.
58. Littleton J, Zieglgänsberger W, (2003) Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 12: s3-s11.
59. Lubman DI, Yücel M, Pantelis C, (2004) Addiction, a condition of compulsive behaviour? Neuroimaging and neuropsychological evidence of inhibitory dysregulation. Addiction 99: 1491-1502.
60. Lukas SE, Lowen SB, Lindsey KP, Conn N, Tartarini W, Rodolico J, Mallya G, Palmer C, Penetar DM, (2013) Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study. Neuroimage 78: 176-185.
61. Mann K, Vollstadt-Klein S, Reinhard I, Lemenager T, Fauth-Buhler M, Hermann D, Hoffmann S, Zimmermann US, Kiefer F, Heinz A, Smolka MN, (2014) Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging. Alcohol Clin Exp Res 38: 2754-2762.
62. Marlatt GA, (1990) Cue exposure and relapse prevention in the treatment of addictive behaviors. Addict Behav 15: 395-399.
63. McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, Baker TB, (2008) A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. Nicotine Tob Res 10: 717-729.
64. McClernon FJ, Hiott FB, Liu J, Salley AN, Behm FM, Rose JE, (2007) Selectively reduced responses to smoking cues in amygdala following extinction-based smoking cessation: results of a preliminary functional magnetic resonance imaging study. Addict Biol 12: 503-512.
65. Mei W, Zhang JX, Xiao Z, (2010) Acute effects of sublingual buprenorphine on brain responses to heroin-related cues in early-abstinent heroin addicts: an uncontrolled trial. Neuroscience 170: 808-815.
66. Menossi HS, Goudriaan AE, de Azevedo-Marques PC, Nicastri S, de Andrade AG, D'Elia G, Li CS, Castaldelli-Maia JM, (2013) Neural bases of pharmacological treatment of nicotine dependence-insights from functional brain imaging: a systematic review. CNS Drugs 27: 921-941.
67. Miller WR, Tonigan JS, (1996) Assessing drinkers' motivation for change: the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES). Psychol Addict Behav 10: 81-89.
68. Monti PM, Rohsenow DJ, Hutchison KE, (2000) Toward bridging the gap between biological, psychobiological and psychosocial models of alcohol craving. Addiction 95: S229-236.
69. Myers KM, Carlezon WA Jr, (2012) d -Cycloserine effects on extinction of conditioned responses to drug-related cues. Biol Psychiatry 71: 947-955.
70. Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K, (2008) Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry 65: 466-475.
71. Myrick H, Li X, Randall PK, Henderson S, Voronin K, Anton RF, (2010) The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol 30: 365-372.
72. Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, Randall CL, (2009) A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res 33: 1582-1588.
73. Nestler EJ, (2005) Is there a common molecular pathway for addiction? Nat Neurosci 8: 1445-1449.
74. Olive MF, Cleva RM, Kalivas PW, Malcolm RJ, (2012) Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav 100: 801-810.
75. Parvaz MA, Alia-Klein N, Woicik PA, Volkow ND, Goldstein RZ, (2011) Neuroimaging for drug addiction and related behaviors. Rev Neurosci 22: 609-624.
76. Perkins KA, (2009) Does smoking cue-induced craving tell us anything important about nicotine dependence? Addiction 104: 1610-1616.
77. Perkins KA, Lerman C, Fonte CA, Mercincavage M, Stitzer ML, Chengappa KN, Jain A, (2010) Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clin Pharmacol Ther 88: 109-114.
78. Prisciandaro JJ, McRae-Clark AL, Myrick H, Henderson S, Brady KT, (2014) Brain activation to cocaine cues and motivation/treatment status. Addict Biol 19: 240-249.
79. Prisciandaro JJ, Myrick H, Henderson S, McRae-Clark AL, Brady KT, (2013a) Prospective associations between brain activation to cocaine and no-go cues and cocaine relapse. Drug Alcohol Depend 131: 44-49.
80. Prisciandaro JJ, Myrick H, Henderson S, McRae-Clark AL, Santa Ana EJ, Saladin ME, Brady KT, (2013b) Impact of DCS-facilitated cue exposure therapy on brain activation to cocaine cues in cocaine dependence. Drug Alcohol Depend 132: 195-201.
81. Radua J, Mataix-Cols D, (2012) Meta-analytic methods for neuroimaging data explained. Biol Mood Anxiety Disord 2: 6.
82. Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D, Anton RF, (2012) The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res 36: 385-394.
83. Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED, (2014a) Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. Psychopharmacology (Berl) 231: 3843-3853.
84. Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED, (2014b) Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. Am J Drug Alcohol Abuse 1-10.
85. Reinhard I, Lemenager T, Fauth-Buhler M, Hermann D, Hoffmann S, Heinz A, Kiefer F, Smolka MN, Wellek S, Mann K, Vollstadt-Klein S, (2015) A comparison of region-of-interest measures for extracting whole brain data using survival analysis in alcoholism as an example. J Neurosci Methods 242: 58-64.
86. Robinson TE, Berridge KC, (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18: 247-291.
87. Salamone JD, Correa M, (2012) The mysterious motivational functions of mesolimbic dopamine. Neuron 76: 470-485.
88. Schacht J, Anton R, Randall P, Li X, Henderson S, Myrick H, (2014) Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology (Berl) 231: 3799-3807.
89. Schacht JP, Anton RF, Myrick H, (2013a) Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol 18: 121-133.
90. Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H, (2013b) Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics. Psychopharmacology (Berl) 227: 627-637.
91. Schacht JP, Anton RF, Voronin KE, Randall PK, Li X, Henderson S, Myrick H, (2013c) Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology 38: 414-422.
92. Schneider F, Habel U, Wagner M, Franke P, Salloum JB, Shah NJ, Toni I, Sulzbach C, Hönig K, Maier W, Gaebel W, Zilles K, (2001) Subcortical correlates of craving in recently abstinent alcoholic patients. Am J Psychiatry 158: 1075-1083.
93. Seo D, Lacadie CM, Tuit K, Hong KI, Constable RT, Sinha R, (2013) Disrupted ventromedial prefrontal function, alcohol craving, and subsequent relapse risk. JAMA psychiatry 70: 727-739.
94. Shoptaw S, Yang X, Rotheram-Fuller EJ, Hsieh YC, Kintaudi PC, Charuvastra VC, Ling W, (2003) Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 64: 1440-1448.
95. Simons JS, Wills TA, Emery NN, Marks RM, (2015) Quantifying alcohol consumption: self-report, transdermal assessment, and prediction of dependence symptoms. Addict Behav 50: 205-212.
96. Sinha R, Li CSR, (2007) Imaging stress- and cue-induced drug and alcohol craving: association with relapse and clinical implications. Drug Alcohol Rev 26: 25-31.
97. Stamatakis AM, Sparta DR, Jennings JH, McElligott ZA, Decot H, Stuber GD, (2014) Amygdala and bed nucleus of the stria terminalis circuitry: implications for addiction-related behaviors. Neuropharmacology 76, Part B: 320-328.
98. Versace F, Engelmann JM, Robinson JD, Jackson EF, Green CE, Lam CY, Minnix JA, Karam-Hage MA, Brown VL, Wetter DW, (2014) Prequit fMRI responses to pleasant and cigarette cues predict smoking cessation outcome. Nicotine Tob Res 16: 697-708.
99. Volkow ND, Wang GJ, Fowler JS, Tomasi D, (2012) Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol 52: 321-336.
100. Vollstadt-Klein S, Loeber S, Kirsch M, Bach P, Richter A, Buhler M, von der Goltz C, Hermann D, Mann K, Kiefer F, (2011) Effects of cue-exposure treatment on neural cue reactivity in alcohol dependence: a randomized trial. Biol Psychiatry 69: 1060-1066.
101. Walter M, Denier N, Gerber H, Schmid O, Lanz C, Brenneisen R, Riecher-Rossler A, Wiesbeck GA, Scheffler K, Seifritz E, McGuire P, Fusar-Poli P, Borgwardt S, (2015) Orbitofrontal response to drug-related stimuli after heroin administration. Addict Biol 3: 570-579.
102. Wang DJ, Chen Y, Fernandez-Seara MA, Detre JA, (2011a) Potentials and challenges for arterial spin labeling in pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 337: 359-366.
103. Wang W, Li Q, Wang Y, Tian J, Yang W, Li W, Qin W, Yuan K, Liu J, (2011b) Brain fMRI and craving response to heroin-related cues in patients on methadone maintenance treatment. Am J Drug Alcohol Abuse 37: 123-130.
104. Whelan R, Watts R, Orr CA, Althoff RR, Artiges E, Banaschewski T, Barker GJ, Bokde ALW, Buchel C, Carvalho FM, Conrod PJ, Flor H, Fauth-Buhler M, Frouin V, Gallinat J, Gan G, Gowland P, Heinz A, Ittermann B, Lawrence C, Mann K, Martinot J-L, Nees F, Ortiz N, Paillere-Martinot M-L, Paus T, Pausova Z, Rietschel M, Robbins TW, Smolka MN, Strohle A, Schumann G, Garavan H, the IC (2014) Neuropsychosocial profiles of current and future adolescent alcohol misusers. Nature 512: 185-189.
105. Wiers CE, Stelzel C, Gladwin TE, Park SQ, Pawelczack S, Gawron CK, Stuke H, Heinz A, Wiers RW, Rinck M, Lindenmeyer J, Walter H, Bermpohl F, (2015) Effects of cognitive bias modification training on neural alcohol cue reactivity in alcohol dependence. Am J Psychiatry 172: 335-343.
106. Wilson SJ, Sayette MA, Fiez JA, (2004) Prefrontal responses to drug cues: a neurocognitive analysis. Nat Neurosci 7: 211-214.
107. Wise RA, (1988) The neurobiology of craving: implications for the understanding and treatment of addiction. J Abnorm Psychol 97: 118-132.
108. Xu X, Clark US, David SP, Mulligan RC, Knopik VS, McGeary J, MacKillop J, McCaffery J, Niaura RS, Sweet LH, (2014) Effects of nicotine deprivation and replacement on BOLD-fMRI response to smoking cues as a function of DRD4 VNTR genotype. Nicotine Tob Res 16: 939-947.
109. Yalachkov Y, Kaiser J, Naumer MJ, (2012) Functional neuroimaging studies in addiction: multisensory drug stimuli and neural cue reactivity. Neurosci Biobehav Rev 36: 825-835.
110. Young KA, Franklin TR, Roberts DC, Jagannathan K, Suh JJ, Wetherill RR, Wang Z, Kampman KM, O'Brien CP, Childress AR, (2014) Nipping cue reactivity in the bud: baclofen prevents limbic activation elicited by subliminal drug cues. J Neurosci 34: 5038-5043.
111. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, Prisinzano TE, Baumann MH, (2009) Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 329: 738-746.